Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$120,000.00

Circulating DNA (ctDNA) in patients with metastatic renal cell carcinoma (mRCC) on active surveillance-- an evaluation of the feasibility and prognostic features in a prospective cohort.

FY 2022-23

Summary
Circulating tumour DNA (ctDNA) is an emerging tool in detecting and monitoring cancer activity. In most cancers, ctDNA is released into the blood as tumour cells grow, meaning ctDNA can be detected with blood test. Both the presence of ctDNA ("is it here or not") and the quantity ("how much is present") can be detected with current ctDNA technology. The presence and quantity of ctDNA is associated with worse outcomes in cancer patients--for example, a recent study in colon cancer showed that patients with ctDNA present in their blood after curative surgery are at higher risk for relapse and therefore are encouraged to proceed with chemotherapy following surgery. Detectable ctDNA in kidney cancer is also associated with a worse prognosis. Active surveillance (meaning monitoring to see how fast the cancer is growing rather than initially starting systemic therapy) remains a valid management strategy for some patients with metastatic kidney cancer, as systemic treatment can have side effects that reduce quality of life. Up to 30% of patients are initially managed with active surveillance. However, at the current time there is no way to predict which patients on active surveillance are more likely to experience faster cancer progression. Our study aims to evaluate if ctDNA has a role in better selecting patients with metastatic kidney cancer who are being considered for active surveillance. We will offer patients undergoing active surveillance a periodic ctDNA test to monitor the presence and amount of ctDNA in their blood. We will correlate these levels with the rate of cancer growth seen on imaging studies and with the time patients remain off of systemic therapy. We suspect that patients with detectable ctDNA levels (or higher levels of ctDNA) will experience disease progression sooner than those patients with no detectable ctDNA. If confirmed, ctDNA may prove as a valuable tool for more informed decision making about starting or deferring systemic treatments.
Program
CIHR Fellowship
Location
England, United Kingdom
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
473747
Name
Wells John C
Region
England
Country
United Kingdom
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Circulating DNA (ctDNA) in patients with metastatic renal cell carcinoma (mRCC) on active surveillance-- an evaluation of the feasibility and prognostic features in a prospective cohort.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Circulating Tumour Dna; Ctdna; Kidney Cancer; Outcomes; Renal Cell Carcinoma; Surveillance
Abstract
Circulating tumour DNA (ctDNA) is an emerging tool in detecting and monitoring cancer activity. In most cancers, ctDNA is released into the blood as tumour cells grow, meaning ctDNA can be detected with blood test. Both the presence of ctDNA ("is it here or not") and the quantity ("how much is present") can be detected with current ctDNA technology. The presence and quantity of ctDNA is associated with worse outcomes in cancer patients--for example, a recent study in colon cancer showed that patients with ctDNA present in their blood after curative surgery are at higher risk for relapse and therefore are encouraged to proceed with chemotherapy following surgery. Detectable ctDNA in kidney cancer is also associated with a worse prognosis. Active surveillance (meaning monitoring to see how fast the cancer is growing rather than initially starting systemic therapy) remains a valid management strategy for some patients with metastatic kidney cancer, as systemic treatment can have side effects that reduce quality of life. Up to 30% of patients are initially managed with active surveillance. However, at the current time there is no way to predict which patients on active surveillance are more likely to experience faster cancer progression. Our study aims to evaluate if ctDNA has a role in better selecting patients with metastatic kidney cancer who are being considered for active surveillance. We will offer patients undergoing active surveillance a periodic ctDNA test to monitor the presence and amount of ctDNA in their blood. We will correlate these levels with the rate of cancer growth seen on imaging studies and with the time patients remain off of systemic therapy. We suspect that patients with detectable ctDNA levels (or higher levels of ctDNA) will experience disease progression sooner than those patients with no detectable ctDNA. If confirmed, ctDNA may prove as a valuable tool for more informed decision making about starting or deferring systemic treatments.
Competitiondate
202210
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Wells, John C
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~
Direct Payment - $120,000 Grant (2022-23) | Canada Spends